Rapid testing saves lives.

Building a better tomorrow

About Us

Born out of Brigham Young University, Diagnostic Ventures is a proud Utah-native startup on a mission to transform sepsis care. We are engineering a diagnostic solution that replaces traditional blood cultures, eliminating critical wait times and empowering providers to save lives.

‍Disclaimer: This product is currently under development and is not yet FDA-approved or available for commercial sale.

Our Solution

Rapid Pathogen ID/AST

Our technology isolates pathogens directly from a whole blood, bypassing traditional culture processes. It then uses raman spectroscopy and machine learning to quickly identify bacteria, followed by microfluidic testing for a comprehensive microbial AST.


1. Zanotti-Cavazzoni S. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.  Yearbook of Critical Care Medicine. 2007; 2007:187-188. doi:10.1016/s0734-3299(08)70339-3.

2. Global Sepsis Alliance, 2024

3. Rudd et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study, 2020.